AbbVie
ABBV
$263.04
+0.49%
AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with flagship products including Skyrizi, Rinvoq, Botox, Vraylar, and Imbruvica, following its 2013 spin-off from Abbott and the transformative 2020 Allergan acquisition. The company has successfully transitioned from its historical dependence on Humira — now facing biosimilar erosion — into a diversified, multi-franchise platform, with Skyrizi and Rinvoq emerging as the new growth engine and Botox anchoring a leading medical aesthetics franchise. The current investor narrative centers on the durability of this post-Humira growth story, with recent headlines highlighting the $10.9 billion Apogee Therapeutics acquisition to extend immunology dominance, a new 52-week high reached in late June 2026, and debate over whether the stock has become too expensive after its strong run. Management's aggressive pipeline expansion into weight-loss and eczema drugs, combined with its Dividend King status, has reinforced the bull case, though the Apogee deal's earnings accretion not arriving until 2032 introduces a longer-duration risk to the thesis.…
ABBV
AbbVie
$263.04
Related headlines
Investment Opinion: Should I buy ABBV Today?
We rate AbbVie a Buy, anchored by its successful transition to a diversified growth platform, robust free cash flow, and a forward PE of 15.79x that is reasonable for a large-cap pharma with double-digit revenue growth. The analyst consensus is 'buy' with a mean recommendation of 1.68 and an average target price of $277.31, implying 7.9% upside from the current $257.12. The core thesis is that the market is undervaluing AbbVie's normalized earnings power, as evidenced by the wide gap between trailing PE (96.4x) and forward PE (15.8x). Supporting evidence includes 12.43% YoY revenue growth in Q1 2026, driven by Skyrizi ($4.48B) and Rinvoq ($2.12B); a gross margin of 71.88% and operating margin of 31.56%, reflecting strong profitability; $20.87 billion in trailing free cash flow that easily covers the 2.88% dividend yield; and a PS ratio of 6.63x that, while above the sector median of 4-5x, is justified by AbbVie's superior growth and pipeline. The biggest risks that could invalidate the thesis are: (1) a failure to meet the $20.96 forward EPS consensus, which would collapse the forward PE argument; (2) integration challenges or delays with the $10.9 billion Apogee acquisition, which is not accretive until 2032; and (3) a broader de-rating of pharma multiples due to drug pricing reforms or competitive pressures. We would upgrade to a Strong Buy if forward PE compresses below 14x or if Skyrizi/Rinvoq growth accelerates above 20% YoY; we would downgrade to Hold if revenue growth decelerates below 8% or if net margin fails to recover above 10% by year-end. Relative to its own history, the forward PE is near the low end, and compared to peers, the valuation is fair to slightly undervalued given the growth profile.
Sign up to view all
ABBV 12-Month Price Forecast
AbbVie presents a compelling growth-at-a-reasonable-price opportunity, with the market undervaluing its normalized earnings power as evidenced by the 15.79x forward PE. The successful transition from Humira to Skyrizi/Rinvoq is well underway, and the pipeline expansion into weight-loss and eczema drugs, along with the Apogee acquisition, provides long-term optionality. However, the stock's proximity to its 52-week high and the delayed accretion from Apogee introduce near-term risks. We would upgrade to high confidence if Q2 2026 earnings show continued margin recovery and Skyrizi/Rinvoq growth above 20% YoY; we would downgrade to neutral if forward EPS guidance is cut or if the Apogee integration shows signs of trouble.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $278.61 and implied upside of +5.9% versus the current price.
Average Target
$278.61
0 analysts
Implied Upside
+5.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
AbbVie is covered by 29 analysts, with a consensus recommendation of "buy" and a recommendation mean of 1.68 (where 1 is Strong Buy and 5 is Strong Sell), indicating a bullish tilt. The average target price is $277.31, which implies approximately 7.9% upside from the current price of $257.12. The consensus leans moderately bullish, with the majority of recent ratings from major firms — including UBS (Neutral), BMO Capital (Outperform), Wells Fargo (Overweight), B of A Securities (Buy), RBC Capital (Outperform), JP Morgan (Overweight), Guggenheim (Buy), Cantor Fitzgerald (Overweight), Canaccord Genuity (Buy), and Piper Sandler (Overweight) — clustered in the Buy/Overweight camp. The estimated EPS average of $20.96 for the forward period, with a range of $20.32 to $21.41, suggests analysts expect a significant earnings recovery, which underpins the bullish targets. The target range spans from a low of $200 to a high of $328, a spread of $128 or 64% of the low target, indicating meaningful dispersion in analyst views. The high target of $328 implies approximately 27.6% upside and likely assumes successful execution on the Apogee acquisition, continued Skyrizi/Rinvoq momentum, and multiple expansion as earnings normalize. The low target of $200 implies roughly 22.2% downside and likely prices in risks such as slower-than-expected immunology growth, competitive pressures, integration challenges from recent acquisitions, or a broader market de-rating of pharma multiples. The wide spread signals high uncertainty, though the clustering of ratings in the Buy/Overweight category suggests stronger conviction on the bullish side. Recent institutional ratings show no downgrades, with all actions being reiterations of existing positive ratings, indicating stable analyst sentiment. The estimated revenue average of $84.82 billion for the forward period, with a range of $82.83 billion to $86.21 billion, provides a solid top-line foundation for the earnings recovery thesis.
Drowning in data?
Find the real signal!
Bulls vs Bears: ABBV Investment Factors
The bull case for AbbVie rests on its successful post-Humira transformation, with Skyrizi and Rinvoq driving double-digit revenue growth and a forward PE of 15.79x that appears reasonable. The bear case highlights elevated trailing valuation multiples, net margin volatility, and balance sheet leverage, with the Apogee acquisition's delayed accretion adding long-term uncertainty. Currently, the bull evidence is stronger: revenue growth is accelerating, free cash flow is robust, and analyst consensus is firmly bullish with a $277.31 average target. The most critical tension is whether the market's earnings recovery expectations—implied by the gap between 96.4x trailing and 15.8x forward PE—will materialize; if they do, the stock is undervalued, but any shortfall could trigger a sharp de-rating.
Bullish
- Revenue growth accelerating post-Humira: Q1 2026 revenue grew 12.43% YoY to $15.00 billion, driven by Skyrizi ($4.48B) and Rinvoq ($2.12B), which together more than offset Humira's decline to $688 million. This demonstrates a successful transition from the legacy franchise to a diversified growth platform.
- Attractive forward valuation: The forward PE of 15.79x is near the low end of AbbVie's historical range and roughly in line with the large-cap pharma sector average of 15-20x. With estimated EPS of $20.96 for the forward period, the stock is reasonably priced relative to its growth profile.
- Strong free cash flow supports dividend: Trailing twelve-month free cash flow is $20.87 billion, comfortably covering the $3.09 billion in quarterly dividends. The dividend yield of 2.88% exceeds the sector average of ~2.5%, and the payout ratio of 275.8% on GAAP earnings is distorted by non-cash items; cash flow coverage remains robust.
- Analyst consensus bullish with upside: 29 analysts rate ABBV a 'buy' with a mean recommendation of 1.68 and an average target price of $277.31, implying 7.9% upside from the current $257.12. The high target of $328 suggests 27.6% upside if pipeline execution exceeds expectations.
Bearish
- Elevated trailing valuation metrics: The trailing PE of 96.41x and EV/EBITDA of 26.61x are significantly above historical pharma averages, reflecting a depressed earnings base. While forward PE is reasonable, the high trailing multiples suggest the market is pricing in flawless execution of the earnings recovery.
- Net margin volatility and earnings quality: Q1 2026 net margin was only 4.66%, down from 9.64% in Q1 2025, due to a $3.70 billion swing in other income/expenses and high interest expense of $717 million. This volatility raises concerns about earnings predictability and the impact of acquisition-related costs.
- Balance sheet leverage and negative equity: The debt-to-equity ratio is -21.12 (reflecting negative equity from buybacks and acquisitions), and the current ratio of 0.67 indicates current liabilities exceed current assets. This leverage could constrain financial flexibility if cash flow deteriorates or interest rates rise.
- Apogee acquisition accretion delayed to 2032: The $10.9 billion Apogee Therapeutics deal is expected to be earnings-accretive only by 2032, introducing a long-duration risk. Until then, it may dilute near-term earnings and increase integration complexity without immediate financial benefit.
ABBV Technical Analysis
AbbVie is in a sustained uptrend, with the stock up 16.76% over the past year and trading at 257.12, which represents approximately 86.8% of its 52-week range (low of 190.75, high of 267.47). This positioning near the upper end of the range signals strong momentum but also raises the risk of overextension, particularly given the stock's sharp advance from its March 2026 lows around 197. The 52-week high of 267.47 was set in late August 2026, and the current price sits just 3.9% below that peak, suggesting the market remains constructive on the name despite recent consolidation. The stock's beta of 0.281 indicates it is significantly less volatile than the broader market — roughly 72% less volatile than SPY — which is characteristic of a defensive healthcare large-cap and implies lower position-sizing risk for momentum traders. Recent momentum has been positive but decelerating: the 1-month change of 3.36% and 3-month change of 12.91% show the stock has cooled from its mid-year surge, when it rallied from 216 in mid-June to 263 by late July. The 6-month change of 17.04% and YTD gain of 12.13% confirm the longer-term trend remains intact, but the 1-month figure trailing the 3-month figure suggests momentum is moderating rather than accelerating. Relative strength versus SPY is notably strong across all timeframes — 4.42% over 1 month, 9.87% over 3 months, and 0.54% over 1 year — indicating AbbVie is outperforming the market, though the 1-year relative strength is marginal, reflecting SPY's own 16.22% gain. Key technical support lies at the 52-week low of 190.75, with intermediate support around the 245-248 area where the stock consolidated in early August; resistance is at the 52-week high of 267.47, and a breakout above that level would signal renewed momentum and potentially open the door to the analyst high target of 328. A breakdown below 245 would suggest a deeper pullback toward the 220-230 zone, while a move below 190.75 would represent a significant trend reversal. The max drawdown of -19.23% over the period underscores that even low-beta names can experience meaningful corrections, and the short ratio of 4.0 indicates moderate short interest that could fuel a squeeze on a breakout.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$191-$267
Price range past year
Annual Return
+20.9%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +5.4% | -2.4% |
| 3m | +18.9% | +2.2% |
| 6m | +27.5% | +14.8% |
| 1y | +20.9% | +14.6% |
| ytd | +14.7% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
AbbVie's revenue trajectory is robust, with Q1 2026 revenue of $15.00 billion representing 12.43% year-over-year growth from $13.34 billion in Q1 2025, continuing a multi-quarter expansion that has seen revenue climb from $14.46 billion in Q2 2024 to $16.62 billion in Q4 2025. The growth is driven by the immunology franchise, where Skyrizi generated $4.48 billion and Rinvoq $2.12 billion in the most recent quarter, more than offsetting Humira's decline to $688 million as biosimilar competition erodes the legacy drug. Neuroscience products are also contributing meaningfully, with Vraylar at $905 million, Botox Therapeutic at $1.01 billion, and the migraine portfolio (Qulipta at $296 million, Ubrelvy at $339 million) adding diversification. The aesthetics segment, including Botox Cosmetic at $668 million and Juvederm at $232 million, provides a higher-margin, cash-generative complement to the pharmaceutical core, though it remains sensitive to consumer discretionary spending. The revenue trend implies the company has successfully navigated the Humira patent cliff, and the 12.4% growth rate is impressive for a company of AbbVie's size, suggesting the investment case has shifted from a turnaround story to a sustainable growth narrative. Profitability remains solid but with notable quarterly volatility: Q1 2026 net income was $699 million on a 4.66% net margin, down from $1.29 billion and 9.64% in Q1 2025, largely due to a $3.70 billion swing in other income/expenses and higher interest expense of $717 million. Gross margin has been stable and strong, ranging from 66.4% to 72.6% over the past eight quarters, with Q1 2026 at 71.88%, reflecting the high-margin nature of branded pharmaceuticals. Operating margin was 31.56% in Q1 2026, down from 34.96% in Q4 2025 but consistent with the 27-35% range seen over the past two years, and the trailing twelve-month net margin of 6.91% is depressed by one-time items and acquisition-related costs. The company's gross margin of 70.24% is typical for large-cap pharma, and the operating margin of 32.85% is healthy, though the net margin volatility — driven by items like the $3.70 billion other expense in Q1 2026 — warrants monitoring. The balance sheet carries meaningful leverage, with a debt-to-equity ratio of -21.12 (reflecting negative equity from accumulated buybacks and acquisitions) and a current ratio of 0.67, indicating current liabilities exceed current assets. However, free cash flow remains robust at $20.87 billion on a trailing twelve-month basis, with Q1 2026 FCF of $3.56 billion and Q4 2025 FCF of $4.89 billion, providing ample coverage for the $3.09 billion in quarterly dividends. The dividend payout ratio of 275.8% on a GAAP basis is elevated due to depressed net income, but the dividend yield of 2.88% is attractive and well-covered by cash flow. ROE of -129.2% is distorted by negative equity, while ROA of 10.51% is solid for the sector. The company's cash flow generation is sufficient to fund its dividend, modest buybacks ($1.49 billion in Q1 2026), and strategic acquisitions like Apogee, though the reliance on debt for large deals remains a risk if rates rise or cash flow deteriorates.
Quarterly Revenue
$15.0B
2026-03
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
71.9%
Latest Quarter
Free Cash Flow
$20.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
With trailing net income positive at $699 million in Q1 2026, the PE ratio is the appropriate primary metric, and AbbVie's trailing PE of 96.41x is exceptionally high, reflecting the depressed trailing earnings base rather than a premium valuation. The forward PE of 15.79x tells a dramatically different story, implying the market expects earnings to normalize sharply — the gap between 96.4x trailing and 15.8x forward suggests analysts anticipate a substantial recovery in net income, consistent with the estimated EPS average of $20.96 for the forward period versus the trailing EPS of $0.01. This massive divergence indicates the trailing PE is not meaningful for valuation purposes, and the forward PE of 15.8x is the more relevant metric, which appears reasonable for a large-cap pharma with mid-single-digit to low-double-digit growth. On a price-to-sales basis, AbbVie trades at 6.63x, and its EV/EBITDA of 26.61x and EV/Sales of 8.00x are elevated relative to historical pharma averages. Compared to the broader Drug Manufacturers - General industry, AbbVie's forward PE of 15.8x is roughly in line with or slightly below the sector average, which typically ranges from 15x to 20x for large-cap pharma. The PS ratio of 6.63x is above the sector median of approximately 4-5x, reflecting AbbVie's premium growth profile and strong immunology franchise. The PEG ratio of -77.13 is not meaningful due to negative or distorted earnings growth inputs, and the PB ratio of -123.96 reflects negative book equity, making it useless as a valuation tool. The dividend yield of 2.88% is above the sector average of roughly 2.5%, supporting the income-oriented case. The premium on PS and EV/EBITDA is justified by AbbVie's superior growth trajectory (12.4% revenue growth) and its successful pipeline transition, though the high EV/EBITDA of 26.6x suggests the market is pricing in significant future cash flow growth. Historically, AbbVie's PE ratio has ranged from 14.8x in Q4 2021 to 581.8x in Q3 2025, with the current trailing PE of 96.4x near the higher end of that range but well below the Q3 2025 peak. The PS ratio of 6.63x is actually below the historical average of approximately 20-26x seen in 2024-2025, though those figures were distorted by the Allergan acquisition accounting and Humira transition. On a forward basis, the 15.8x PE is near the lower end of the historical range, suggesting the stock is not expensive when normalized earnings are considered. The market appears to be pricing in a successful execution of the Skyrizi/Rinvoq ramp and the Apogee pipeline, with the current valuation offering a reasonable entry point for long-term investors if those expectations are met.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.6x
Enterprise Value Multiple
Investment Risk Disclosure
AbbVie faces financial risks stemming from its significant debt load and negative equity, with a debt-to-equity ratio of -21.12 and a current ratio of 0.67, indicating current liabilities exceed current assets. The company's net margin has been volatile, dropping to 4.66% in Q1 2026 from 9.64% a year earlier, largely due to a $3.70 billion swing in other income/expenses and high interest expense of $717 million. While free cash flow of $20.87 billion comfortably covers the $3.09 billion quarterly dividend, the payout ratio of 275.8% on GAAP earnings highlights the reliance on non-GAAP adjustments and could pressure the dividend if cash flow deteriorates. Additionally, the $10.9 billion Apogee acquisition, while strategic, adds integration risk and delays earnings accretion until 2032, potentially straining near-term financial flexibility. Market and competitive risks include the high trailing valuation multiples—PE of 96.41x and EV/EBITDA of 26.61x—which leave little room for error and could compress if growth slows. The immunology space is highly competitive, with rivals like Eli Lilly and Vertex advancing in immunology and other therapeutic areas, as noted in recent news about merger mania and pipeline successes. AbbVie's low beta of 0.281 offers defensive characteristics but also means it may lag in strong bull markets; however, its premium PS ratio of 6.63x versus the sector median of 4-5x makes it vulnerable to sector rotation if investors favor cheaper peers. Regulatory headwinds, such as potential drug pricing reforms, and the consumer discretionary sensitivity of the aesthetics segment (Botox Cosmetic at $668 million, Juvederm at $232 million) add further external risks. In a worst-case scenario, a combination of slower-than-expected Skyrizi/Rinvoq growth, integration missteps with Apogee, and a broader market de-rating of pharma multiples could drive the stock down to its 52-week low of $190.75, representing a 25.8% decline from the current price of $257.12. The analyst low target of $200 implies a 22.2% downside, and the historical max drawdown of -19.23% shows that even low-beta names can experience significant corrections. If earnings recovery fails to materialize—evidenced by forward EPS missing the $20.96 consensus—the stock could retest the $200 level, and a break below $190.75 would signal a deeper trend reversal, potentially erasing over a year of gains.
FAQ
The most severe risk is earnings disappointment: if forward EPS misses the $20.96 consensus, the stock could fall to the analyst low target of $200 (22.2% downside). Financial risks include a debt-to-equity ratio of -21.12 and a current ratio of 0.67, which could limit flexibility if cash flow declines. Competitive risks are rising in immunology, with rivals like Eli Lilly and Vertex advancing, potentially eroding AbbVie's market share. Macro risks include drug pricing reforms and interest rate sensitivity, though the low beta of 0.281 provides some insulation. Additionally, the $10.9 billion Apogee acquisition adds integration risk and delays accretion until 2032.
Our 12-month forecast has a base case (55% probability) of $270-$290, assuming EPS of $20.96 and revenue of $84.82 billion, in line with analyst estimates. The bull case (25% probability) targets $300-$328, driven by faster Skyrizi/Rinvoq growth and pipeline success. The bear case (20% probability) targets $200-$220, if earnings miss or competitive pressures intensify. The most likely scenario is the base case, with the key assumption that AbbVie continues to execute on its immunology growth strategy and meets consensus expectations. The average analyst target of $277.31 aligns with our base case midpoint.
On a forward basis, ABBV appears undervalued, with a forward PE of 15.79x versus a trailing PE of 96.41x, reflecting expected earnings normalization. The PS ratio of 6.63x is above the sector median of 4-5x, but justified by AbbVie's 12.43% revenue growth and premium immunology franchise. Compared to its own history, the forward PE is near the low end, suggesting the market is not fully pricing in the earnings recovery. However, the EV/EBITDA of 26.61x is elevated, indicating that the market expects significant future cash flow growth. Overall, the valuation is fair to slightly undervalued if the company meets its $20.96 EPS consensus.
From a risk/reward perspective, ABBV is a good buy for long-term investors, with 7.9% upside to the analyst average target of $277.31 and a reasonable forward PE of 15.79x. The company's 12.43% revenue growth and $20.87 billion free cash flow support the thesis, while the 2.88% dividend yield adds income. However, the stock trades just 3.9% below its 52-week high, and the bear case target of $200 implies 22.2% downside, so near-term risk is elevated. It is most suitable for investors with a 3-5 year horizon who can tolerate volatility and seek exposure to a defensive healthcare leader with growth potential.
ABBV is best suited for long-term investment, given its low beta of 0.281, stable dividend yield of 2.88%, and multi-year pipeline catalysts like the Apogee acquisition that won't contribute until 2032. The stock's defensive characteristics and consistent free cash flow make it ideal for a buy-and-hold strategy, with a suggested minimum holding period of 3-5 years to fully realize the earnings recovery and pipeline potential. Short-term trading is less attractive due to the stock's low volatility and the risk of consolidation near its 52-week high. However, momentum traders could target a breakout above $267.47, but with tighter stops given the 19.23% max drawdown.